Anti-Hypertensive Drugs - Southern Asia

Southern Asia

The Southern Asian region is expected to witness significant growth in the Anti-Hypertensive Drugs market.
By 2024, the projected revenue is estimated to reach US$250.10m.
Furthermore, the market is anticipated to exhibit a compound annual growth rate (CAGR) of 0.56% between 2024 and 2028, resulting in a market volume of US$255.70m by 2028.
When comparing the global landscape, United States is expected to generate the highest revenue in the Anti-Hypertensive Drugs market.
In 2024, the revenue United States is estimated to be US$12,290.00m.
In Southern Asia, India is experiencing a surge in the demand for generic anti-hypertensive drugs due to their affordability and accessibility.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Southern Asia is increasing steadily due to several factors.

Customer preferences: The customers in Southern Asia have become more aware of the benefits of Anti-Hypertensive Drugs in managing high blood pressure. As a result, they are more willing to use these drugs as a preventive measure to avoid health complications in the future. Additionally, the aging population in this region also contributes to the growing demand for these drugs.

Trends in the market: India is the largest market for Anti-Hypertensive Drugs in Southern Asia. The market is dominated by generic drugs due to their affordability. However, there is a growing demand for branded drugs due to their effectiveness and better quality. Furthermore, the trend of online pharmacies has also contributed to the growth of the Anti-Hypertensive Drugs market in Southern Asia.

Local special circumstances: One of the unique features of the Anti-Hypertensive Drugs market in Southern Asia is the prevalence of traditional medicine. Many people in this region still rely on traditional medicine to manage their health conditions. However, there is a growing acceptance of modern medicine, including Anti-Hypertensive Drugs, due to their proven effectiveness.

Underlying macroeconomic factors: The economic growth in Southern Asia has led to an increase in disposable income, which has made healthcare more affordable for many people. Additionally, the governments in this region are investing heavily in healthcare infrastructure, which has improved access to healthcare services. These factors have contributed to the growth of the Anti-Hypertensive Drugs market in Southern Asia.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.